Lanadelumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Lanadelumab: Evidence Pack Incomplete — Repurposing Evaluation Pending
One-Sentence Summary
Lanadelumab (DrugBank: DB14597) has been queried through the data pipeline, but the current Evidence Pack contains no original indication data, no TxGNN predicted indications, and two unresolved data gaps (one Blocking, one High severity). A full repurposing evaluation cannot be completed until these gaps are remediated — this report documents the current data state and outlines the steps required to proceed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | — (no data retrieved) |
| Predicted New Indication | — (TxGNN predictions not yet generated) |
| TxGNN Prediction Score | — |
| Evidence Level | N/A — prediction pipeline has not produced output |
| Finland Market Status | Not marketed (0 authorizations) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why No Mechanistic Analysis Is Possible
Currently, detailed mechanism of action data is not available for Lanadelumab in this Evidence Pack.
Two data gaps block the mechanistic reasoning step:
- DG002 (High severity) — MOA is missing from the DrugBank query results. Without this, it is impossible to draw a mechanistic link between any original indication and a predicted new indication.
- DG001 (Blocking severity) — TFDA package insert warnings and contraindications have not been parsed. This prevents the mandatory Safety Pre-Screen (S1) from running.
Until DG001 is resolved, the pipeline cannot advance to safety evaluation. Until DG002 is resolved, any predicted indication cannot be assessed for biological plausibility.
Finland Market Information
Lanadelumab is not currently marketed in Finland. No marketing authorizations were found in the regulatory query conducted on 2026-03-29.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack has zero predicted indications and contains a Blocking-severity data gap (missing regulatory safety data), making it technically and ethically premature to issue any repurposing recommendation.
To proceed, the following is needed:
- [DG001 — Blocking] Download the TFDA package insert PDF for Lanadelumab and parse warnings, contraindications, and special population restrictions. This is a prerequisite before any safety pre-screen can run.
- [DG002 — High] Query DrugBank API (
/drugs/DB14597) to retrieve the mechanism of action, pharmacodynamics, and drug categories. This is required for mechanistic plausibility analysis. - Re-run the TxGNN prediction pipeline for DB14597 to generate
predicted_indicationswith scores, supporting clinical trials, and literature. - Once predictions are available, re-generate this Evidence Pack (v5+) and run a full L1–L5 evidence evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.